Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT04697628
- Locations
- 🇺🇸
Willis-Knighton Physician Network/Gynecologic Oncology Associates, Shreveport, Louisiana, United States
🇺🇸Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇮🇹Fondazione Policlinico Universitario Agostino, Roma, Other, Italy
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 244
- Registration Number
- NCT04686305
- Locations
- 🇹🇷
Research Site, Bornova-Izmir, Turkey
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2022-08-02
- Target Recruit Count
- 27
- Registration Number
- NCT04683965
- Locations
- 🇨🇳
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 44
- Registration Number
- NCT04638582
- Locations
- 🇨🇦
McGill University Health Center, Montréal, Quebec, Canada
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 468
- Registration Number
- NCT04623775
- Locations
- 🇺🇸
Local Institution - 0147, Pittsburgh, Pennsylvania, United States
🇧🇪Local Institution - 0131, Ghent, Belgium
🇧🇪Local Institution - 0125, Roeselare, Belgium
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 68
- Registration Number
- NCT04622007
- Locations
- 🇺🇸
Texas Oncology - Memorial City, Houston, Texas, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Ventura - UCLA, Ventura, California, United States
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 542
- Registration Number
- NCT04619797
- Locations
- 🇧🇪
Vitaz, Sint Niklaas, Belgium
🇫🇷CHU Strasbourg - Nouvel Hopital Civil, Strasbourg, France
🇯🇵The Cancer Institute Hospital of JFCR, Tokyo, Japan
A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT04611776
Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 226
- Registration Number
- NCT04592666
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Maximilian Diehn
- Target Recruit Count
- 48
- Registration Number
- NCT04585490
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.